ClinicalTrials.gg
RecruitingNCT04619823VIRIMAUpdated May 23, 2024

Virological and Immunological Determinants of Arbovirus Infection in New Caledonia

An interventional study of Blood sample collection in Arbovirus Infections, Zika and Dengue, sponsored by Institut Pasteur. Recruiting at 1 site in New Caledonia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-23.

Primary conditionDengueRegistry: Arbovirus InfectionsReclassifiedWhy we changed it
Registry
Arbovirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Dengue
Why
  1. The study's listed conditions name Dengue, a narrower term within Arbovirus Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Institut Pasteur · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, particularly in tropical and sub-tropical countries. In New Caledonia, dengue epidemics are recurrent and may be associated with the co-circulation of other arboviruses such as Zika or chikungunya.

The virological determinants which condition the occurrence of these epidemics may be linked to an increased vectorial competence of the vector mosquito Aedes aegypti for a particular viral isolate. In fact, the Aedes aegypti mosquito is infected by making a blood meal on a person infected with an arbovirus. The virus infects its digestive tract, then spreads throughout the mosquito's body until it reaches its salivary glands. The virus is then present in the saliva and will be injected into the human host during a new blood meal. Some viral variants are best transmitted by Aedes aegypti. In general, the study of this vectorial competence is carried out by experiments in the laboratory during which an artificial blood meal composed of mammalian blood (human, rabbit, etc.) is mixed with a viral stock. Carrying out deported blood meals during which blood collected from patients infected with an arbovirus is used to gorge mosquitoes makes it possible to place oneself in experimental conditions as close as possible to the natural cycle of transmission of arboviruses.

In the human host, cells of the myeloid lineage present in the peripheral blood constitute preferred targets of replication for arboviruses. At the same time, the peripheral blood cells of patients are activated in response to infection and secrete many soluble factors released into the blood of patients. The study of blood samples from patients infected with arboviruses is therefore of prime importance for understanding both the replicative mechanisms of arboviruses but also the immune response they induce.

Read the detailed description

Collection of blood samples from adult patients with clinical signs suggestive of arbovirus

This study is a interventional study that present minimal risks and constraints.

This study will improve :

  • the reliability of the results of vector competence experiments
  • the understanding of the mechanisms of infection and replication of arboviruses
  • the knowledge of the immune mechanisms involved in the response to infection by an arbovirus
02

Conditions studied

  • Arbovirus Infections
  • Zika
  • Dengue
  • Chikungunya

Browse trials for

Keywords

  • New Caledonia
03

In context

Dengue Reclassified

283 studies on the registry are indexed under Dengue; 44 are open to participants now.

This study's planned enrollment of 250 is above the median of 132 across 197 interventional studies indexed under Dengue.

Browse Dengue studies →

Lead sponsor

Institut Pasteur is the lead sponsor of 99 studies on the registry; 41 are open to participants now.

Compared within Dengue, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Arbovirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Major patient
  • Patient with clinical signs suggestive of an arbovirus infection:

Fever And at least 2 clinical signs suggestive of arbovirus among which myalgia, retro-orbital pain, drop in (if data available), digestive symptoms, etc.

  • Appearance of clinical signs suggestive of an arbovirus infection in the 7 days preceding the blood sample.
  • Patient informed of the performance of the research, the collection of data and biological samples
  • Patient who has given their consent to participate in the research by authorizing the collection of data, the collection of an additional blood sample and the use of this sample

Exclusion criteria

Exclusion Criteria:

  • Patient suffering from another identified virosis, an inflammatory disease or taking anti-inflammatory drugs
  • Pregnant patient
  • Patient returning from a trip within 15 days before the onset of the signs,
  • Patient for whom the blood sample is incomplete or could not be performed
  • Patient's condition, which, in the doctor's opinion, is incompatible with the additional sample required by the study
  • Patient not having consented to participate in the research
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Other
    Patient infected by arboviruses

    Other: Blood sample collection

Interventions

  • OtherBlood sample collection

    Blood sample collection Mosquito collection at home

06

What researchers measure

Primary outcomes

  1. Measurement of vector competence parameters of Aedes aegypti (carriers or not of Wolbachia) for arboviruses by vector competence experiments using deported blood meals.

    Rate of infection of Aedes aegypti (carriers or not of Wolbachia) for arboviruses

    Time frame: 5 years

  2. Measurement of vector competence parameters of Aedes aegypti (carriers or not of Wolbachia) for arboviruses by vector competence experiments using deported blood meals.

    Measurement of dissemination of Aedes aegypti (carriers or not of Wolbachia) for arboviruses

    Time frame: 5 years

  3. Measurement of vector competence parameters of Aedes aegypti (carriers or not of Wolbachia) for arboviruses by vector competence experiments using deported blood meals.

    Measurement of transmission of Aedes aegypti (carriers or not of Wolbachia) for arboviruses

    Time frame: 5 years

Secondary outcomes

  1. Molecular characterization of arborviruses strains included in the blood of patients and which may be diffused by mosquitoes carrying Wolbachia or not during deported blood meals

    Whole genome sequencing and bioinformatics techniques as well as by in vitro infections of arbovirus strains included in the blood of patients and which may be diffused by mosquitoes carrying Wolbachia or not during deported blood meals

    Time frame: 5 years

  2. Molecular characterization of arborviruses strains contained in mosquitoes present in patients' homes

    Whole genome sequencing and bioinformatics techniques as well as by in vitro infections of arbovirus strains contained in mosquitoes present in patients' homes

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Centre Hospitalier Territorial de Nouvelle-Calédonie
    Dumbéa Sur Mer, New Caledonia
    Recruiting
    • Myrielle Dupont Rouzeyrol, PhD · Contactmdupont@pasteur.nc · +687 27 75 30
    • Cécile Cazorla, MD · Principal investigator
    • Mathieu Sérié, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Feb 2026, 60 months after the start.

Of 30 interventional studies with no phase under Dengue, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's planned 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2020
First posted
Nov 6, 2020
StartActual
Feb 15, 2021
Primary completionEst.
Feb 15, 2026
CompletionEst.
Feb 15, 2026
Last update
May 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04619823
Lead sponsor
Institut Pasteur
Collaborators
Institut Pasteur de Nouvelle-Calédonie, Centre Hospitalier Territorial de Nouvelle-Calédonie
Responsible party
Sponsor
First posted
Nov 6, 2020
Start date
Feb 15, 2021
Primary completion
Feb 15, 2026 (estimated)
Completion
Feb 15, 2026 (estimated)
Last update
May 23, 2024

Study contacts

Myrielle Dupont-Rouzeyrol, PhD
Contact
mdupont@pasteur.nc
+687 27 75 30
Catherine Inizan, PhD
Contact
cinizan@pasteur.fr
+687 27 26 66
Myrielle Dupont-Rouzeyrol, PhD
principal investigator · Institut Pasteur de Nouvelle-Calédonie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion